Kezar Life Sciences (NASDAQ:KZR) Price Target Cut to $9.00 by Analysts at Wells Fargo & Company

Kezar Life Sciences (NASDAQ:KZR) had its target price trimmed by Wells Fargo & Company from $11.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd.

Kezar Life Sciences Price Performance

NASDAQ:KZR opened at $6.38 on Thursday. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $11.35. The stock’s fifty day moving average is $7.42 and its two-hundred day moving average is $6.73. The company has a market capitalization of $46.55 million, a P/E ratio of -0.48 and a beta of 0.25. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25. Equities analysts expect that Kezar Life Sciences will post -5.17 EPS for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd grew its stake in shares of Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after acquiring an additional 37,504 shares in the last quarter. Mackenzie Financial Corp acquired a new position in Kezar Life Sciences during the 2nd quarter worth $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Kezar Life Sciences during the 2nd quarter worth $63,000. Geode Capital Management LLC increased its holdings in Kezar Life Sciences by 15.0% during the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after purchasing an additional 81,678 shares during the period. Finally, Acuitas Investments LLC raised its position in Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after purchasing an additional 295,956 shares in the last quarter. 67.90% of the stock is owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.